Literature DB >> 24421209

Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology.

Vickie Y Jo1, Edmund S Cibas, Geraldine S Pinkus.   

Abstract

BACKGROUND: Adenocarcinoma can be challenging to distinguish from malignant mesothelioma in effusions, and this distinction often requires ancillary studies and clinical correlation. Immunohistochemistry for claudin-4, a tight-junction-associated protein, has recently been shown to distinguish adenocarcinoma from malignant mesothelioma, mostly in surgical specimens. Our aim was to validate and assess the immunoreactivity profile of claudin-4 in a large series of malignant effusions.
METHODS: We evaluated 159 malignant effusions (84 adenocarcinomas and 75 malignant mesotheliomas). Claudin-4 immunohistochemistry was performed on cell-block paraffin sections and scored for staining intensity, staining pattern (cytoplasmic versus membranous), and percentage of positive tumor cells. Appropriate positive and negative controls were used throughout.
RESULTS: All cases of mesothelioma were negative for claudin-4 (0 of 64). Eighty-three of 84 cases of adenocarcinoma were positive (99%); 1 case of serous carcinoma was negative. Most adenocarcinomas showed strong and diffuse membranous staining (71 of 84; 84%); 12 cases (14%) showed membranous staining of moderate intensity. The overall sensitivity for adenocarcinoma was 99% (83 of 84).
CONCLUSIONS: Claudin-4 immunohistochemistry effectively distinguishes adenocarcinoma from malignant mesothelioma with high sensitivity and specificity in the evaluation of malignant effusions.
© 2014 American Cancer Society.

Entities:  

Keywords:  adenocarcinoma; claudin-4; cytology; effusion; mesothelioma

Mesh:

Substances:

Year:  2014        PMID: 24421209     DOI: 10.1002/cncy.21392

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  10 in total

1.  Anti-EpCAM antibodies for detection of metastatic carcinoma in effusions and peritoneal wash.

Authors:  Fabiana Pirani Carneiro; Maria Imaculada Muniz-Junqueira; Marcos De Vasconcelos Carneiro; Ísis De Araújo Oliveira; Aluízio Carlos Soares; Nathália De Vargas Haar; Gustavo Henrique Soares Takano; Leonora Maciel De Sousa Vianna; Guilherme De Carvalho Caldas; Danillo Leal Marinho Vieira; Lígia Lins Frutuoso; Larissa Matos Rodrigues Brito; Rafael Vieira Martins De Siqueira; Amanda Moreira Parente; Tercia Maria Mendes Lousa De Castro; Isabela Peres; Lianna Martha Soares Mendes; Tatiana Karla Dos Santos Borges; Vânia Moraes Ferreira; Andrea Barretto Motoyama
Journal:  Oncol Lett       Date:  2019-06-12       Impact factor: 2.967

2.  The diagnostic role of PTEN and ARID1A in serous effusions.

Authors:  Ben Davidson; Maurizio Pinamonti; Dolors Cuevas; Arild Holth; Pio Zeppa; Thomas Hager; Jeremias Wohlschlaeger; Martin Tötsch
Journal:  Virchows Arch       Date:  2017-11-24       Impact factor: 4.064

Review 3.  Immunocytochemistry of effusions: Processing and commonly used immunomarkers.

Authors:  Vinod B Shidham; Beata Janikowski
Journal:  Cytojournal       Date:  2022-01-31       Impact factor: 2.345

4.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

Review 5.  Claudins as biomarkers of differential diagnosis and prognosis of tumors.

Authors:  Olga P Popova; Alla V Kuznetsova; Svetlana Yu Bogomazova; Alexey A Ivanov
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-09       Impact factor: 4.553

6.  Diagnostic accuracy of calretinin for malignant mesothelioma in serous effusions: a meta-analysis.

Authors:  Diandian Li; Bo Wang; Hongyu Long; Fuqiang Wen
Journal:  Sci Rep       Date:  2015-03-30       Impact factor: 4.379

7.  Transcriptomic Analysis of the Claudin Interactome in Malignant Pleural Mesothelioma: Evaluation of the Effect of Disease Phenotype, Asbestos Exposure, and CDKN2A Deletion Status.

Authors:  Erasmia Rouka; Georgios D Vavougios; Evgeniy I Solenov; Konstantinos I Gourgoulianis; Chrissi Hatzoglou; Sotirios G Zarogiannis
Journal:  Front Physiol       Date:  2017-03-21       Impact factor: 4.566

Review 8.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

9.  P16 as a marker of carcinoma in effusions and peritoneal washing.

Authors:  Fabiana Pirani Carneiro; Rivadávio Fernandes Amorim; Marcos de Vasconcelos Carneiro; Tercia Maria Mendes Lousa de Castro; Leonora Maciel de Souza Vianna; Gustavo Henrique Soares Takano; Andersen Charles Daros; Isabela Peres; Selma Aparecida Souza Kuckelhaus; Andrea Barretto Motoyama
Journal:  BMC Cancer       Date:  2020-03-17       Impact factor: 4.430

Review 10.  Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.

Authors:  David B Chapel; Jefree J Schulte; Aliya N Husain; Thomas Krausz
Journal:  Transl Lung Cancer Res       Date:  2020-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.